![Raphaëlle Martin-Neuville](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Raphaëlle Martin-Neuville
Directeur des opérations chez Resilience SAS
Profil
Raphaëlle Martin-Neuville has worked as a Senior Associate at Aster Capital Partners SAS since 2018.
Additionally, they currently hold the position of Operations Manager at Resilience SAS, starting in 2021.
Postes actifs de Raphaëlle Martin-Neuville
Sociétés | Poste | Début |
---|---|---|
Aster Capital Partners SAS
![]() Aster Capital Partners SAS Investment ManagersFinance Aster Capital Partners SAS (Aster Capital) is the French venture capital investment subsidiary of Schneider Electric SA (XP: SU), a world-leading electricity management and industrial automation group. Formerly known as Schneider Electric Ventures SAS, the firm was founded by Jean-Marc Bally in 2000 and changed their name to Aster Capital in 2010. Located in Paris with a representative office in China, the firm manages a venture capital fund sponsored by Schneider Electric and cooperates closely with the group's research scientists. | Analyste en capital-investissement | 01/10/2018 |
Resilience SAS
![]() Resilience SAS Packaged SoftwareTechnology Services Resilience SAS is a French technology-focused biomanufacturing company founded in 2020. The company is based in France, specifically in Garches, and has subsidiaries in the country. The company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to advance the science of biopharmaceutical manufacturing and development to free its partners to focus on the discoveries that improve patients' lives and protect biopharmaceutical supply chains against future disruptions. Resilience is dedicated to broadening access to complex medicines such as biologics, vaccines, nucleic acid, cell/gene therapy modalities, and drug products. Additionally, the company has developed a mobile application aimed at improving the quality of life for patients by measuring, understanding, and alleviating symptoms related to treatments. The company was founded in 2020 by Céline Lazorthes, Drew Oetting, and Jonathan Benhamou, with Jonathan Benhamou serving as the CEO since then. | Directeur des opérations | 01/02/2021 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Aster Capital Partners SAS
![]() Aster Capital Partners SAS Investment ManagersFinance Aster Capital Partners SAS (Aster Capital) is the French venture capital investment subsidiary of Schneider Electric SA (XP: SU), a world-leading electricity management and industrial automation group. Formerly known as Schneider Electric Ventures SAS, the firm was founded by Jean-Marc Bally in 2000 and changed their name to Aster Capital in 2010. Located in Paris with a representative office in China, the firm manages a venture capital fund sponsored by Schneider Electric and cooperates closely with the group's research scientists. | Finance |
Resilience SAS
![]() Resilience SAS Packaged SoftwareTechnology Services Resilience SAS is a French technology-focused biomanufacturing company founded in 2020. The company is based in France, specifically in Garches, and has subsidiaries in the country. The company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to advance the science of biopharmaceutical manufacturing and development to free its partners to focus on the discoveries that improve patients' lives and protect biopharmaceutical supply chains against future disruptions. Resilience is dedicated to broadening access to complex medicines such as biologics, vaccines, nucleic acid, cell/gene therapy modalities, and drug products. Additionally, the company has developed a mobile application aimed at improving the quality of life for patients by measuring, understanding, and alleviating symptoms related to treatments. The company was founded in 2020 by Céline Lazorthes, Drew Oetting, and Jonathan Benhamou, with Jonathan Benhamou serving as the CEO since then. | Technology Services |